ClinicalTrials.gg
CompletedNCT05467722Updated Nov 29, 2022

Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543

A Phase 1 interventional study of CTP-543 in Hepatic Impairment, sponsored by Concert Pharmaceuticals. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-29.

Sponsored by Concert Pharmaceuticals (part of Sun Pharmaceutical Industries Limited) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Sep 2022, 4 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is an open-label, single-dose, single-period, parallel group designed study to determine the effect of mild and moderate hepatic impairment on the pharmacokinetics (PK) of CTP-543 and its major metabolites following administration of a single 12 mg oral dose of CTP-543.

02

Conditions studied

  • Hepatic Impairment

Keywords

  • CTP-543
03

In context

Lead sponsor

Concert Pharmaceuticals is the lead sponsor of 33 studies on the registry; none are open to participants now.

Of its 20 completed or terminated interventional studies of FDA-regulated products, 7 (35%) have results posted.

First submitted before Concert Pharmaceuticals became part of Sun Pharmaceutical Industries Limited.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult males or females aged 18-75
  • (BMI) ≥ 18.0 and ≤ 42.0 kg/m2 at the time of screening
  • If of reproductive age, willing and able to use a medically highly effective form of 30 days prior to first dose, during the study and for 30 days following last dose of study medication
  • Capable of giving and complying with study procedures

Additional Inclusion Criteria for Subjects with Hepatic Impairment:

  • For moderate hepatic impairment, the subject must have a score of 7 to 9 at the time of screening. For mild hepatic impairment, the subject must have a Child- Pugh score of 5 to 6 at the time of screening.
  • No change in disease status within the last 30 days before screening
  • The subject must have a condition consistent with hepatic impairment and associated symptoms, but otherwise be determined to be healthy in the opinion of the Investigator
  • If diabetic, the subject must have the disease controlled

Exclusion criteria

Exclusion Criteria:

  • History of any medical condition, psychiatric disease, social condition, or illness that might confound the results of the study or poses an additional risk to the subject by their participation in the study
  • Known history of any GI surgery or any condition possibly affecting drug absorption
  • History of prolonged syndrome or a QTc interval with Fridericia's correction (QTcF) > 470 msec for males or QTcF > 480 msec for females at Screening visit.
  • Females who are nursing or pregnant prior to drug administration
  • Positive for (HIV)
  • Positive results for coronavirus infection (COVID-19) at screening or check-in
  • Positive drugs of abuse or alcohol results at screening or check in (Day -1)

Additional Exclusion Criteria for Subjects with Hepatic Impairment:

  • History or current diagnosis of uncontrolled or significant cardiac disease
  • Gilbert's syndrome, liver transplant, Wilson's disease, liver disease, esophageal variceal bleeding within 3 months prior to screening
  • Previous diagnosis of hepatocellular carcinoma
  • Acute or exacerbating hepatitis, fluctuating or rapidly deteriorating hepatic function
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    CTP-543 Treatment - Mild Hepatic Impairment

    Drug: CTP-543

  • Experimental
    CTP-543 Treatment - Moderate Hepatic Impairment

    Drug: CTP-543

Interventions

  • Single 12 mg oral dose administered on Day 1

06

What researchers measure

Primary outcomes

  1. Single dose PK exposure: Maximum observed concentration (Cmax)

    Maximum concentration, obtained directly from the observed concentration versus time data.

    Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 36, 48 hours post-dose

  2. Single dose PK exposure: Area Under the Concentration-Time Curve from time zero to the time of the last observed/measured non-zero concentration (AUC0-t)

    Area under the concentration-time curve from time zero (pre-dose) to time of last measurable concentration (calculated by linear-log trapezoidal summation)

    Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 36, 48 hours post-dose

  3. Single dose PK exposure: Area Under the Concentration-Time Curve from time 0 extrapolated to infinity (AUC0-inf)

    Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinity, calculated by linear-log trapezoidal summation and extrapolated to infinity by addition of the last quantifiable concentration divided by the elimination rate constant

    Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 36, 48 hours post-dose

Secondary outcomes

  1. Assessment of Safety and Tolerability following administration of CTP-543

    Number of adverse events, including abnormal clinical laboratory findings, abnormal physical examinations, abnormal ECGs and abnormal vital signs tabulated for each subject

    Time frame: Screening (within 21 days prior to Day 1) through follow-up (7 to 10 days after the final administration of study drug)

07

Study locations

2 sites
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • Alliance for Multispecialty Research, LLC
    Knoxville, Tennessee 37920, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Sep 2022, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2022
First posted
Jul 20, 2022
StartActual
Jun 1, 2022
Primary completionActual
Sep 15, 2022
CompletionActual
Sep 21, 2022
Last update
Nov 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05467722
Responsible party
Sponsor
First posted
Jul 20, 2022
Start date
Jun 1, 2022
Primary completion
Sep 15, 2022
Completion
Sep 21, 2022
Last update
Nov 29, 2022

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deuruxolitinib

Start the discussion